Back to search
FDAFDA · Food and drugs·Recall number Z-0506-2013

Siemens Healthcare BNP (8-type Natriuretic Peptide) 500 Test kit 02816634 100 Test 02816138 10309045, 10309044 028 Intended Use For in vitro diagnostic use in the quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA Centaur and ADVIA Centaur XP systems. This assay is indicated for the measurement of plasma BNP as an aid in the diagnosis and assessment of the severity of heart failure. In patients with acute coronary syndromes (ACS), this test, in conjunction with other known risk factors, can also be used to predict survival as well as to predict the likelihood of future heart failure.

Published December 19, 2012 · Recall initiated: November 14, 2012

Summary

FDA records medical device Class II recall Z-0506-2013, published December 19, 2012 and initiated November 14, 2012. Recalling firm: Siemens Healthcare Diagnostics, Inc; Status: Terminated; Reported quantity: 100 test=24291 and 500 test= 9679; Lot: All lot codes. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Operating range of the ADVIA Centaur systems is 18®C to 30®C (64.4®F to 86.0®F), a change in room temperature may increase or decrease assay results, depending on the specific assay and ADVIA Centaur system used.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Siemens Healthcare Diagnostics, Inc
Distributor
Worldwide Distribution - USA (nationwide) and Internationally to the following countries: Argentina Australia Austria Azerbaijan Belgium Bosnia Herzeg. Brazil Canada Chile COLOMBIA Croatia Czech Republic Denmark Egypt Estonia Finland France Germany Greece Hong Kong Hungary Iceland India Indonesia Iran Ireland Italy Japan Kazakhstan Latvia Lithuania Malaysia Mexico Netherlands New Caledonia Norway Oman P.R. China Philippines Poland Portugal Qatar Rep. of Yemen Republic Korea Reunion Romania Russian Fed. Saudi Arabia Serbia Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Thailand Turkey U.A.E. United Kingdom Uruguay Vietnam
Lot
All lot codes
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Siemens Healthcare BNP (8-type Natriuretic Peptide) 500 Test kit 02816634 100 Test 02816138 10309045, 10309044 028 Intended Use For in vitro diagnostic use in the quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA Centaur and ADVIA Centaur XP systems. This assay is indicated for the measurement of plasma BNP as an aid in the diagnosis and assessment of the severity of heart failure. In patients with acute coronary syndromes (ACS), this test, in conjunction with other known risk factors, can also be used to predict survival as well as to predict the likelihood of future heart failure. recalled?

Yes. FDA published recall Z-0506-2013 on December 19, 2012. Reported hazard: Operating range of the ADVIA Centaur systems is 18®C to 30®C (64.4®F to 86.0®F), a change in room temperature may increase or decrease assay results, depending on the specific assay and ADVIA Centaur system used.

What should I do if I have this product?

Voluntary: Firm initiated · Letter